MARKET WIREYahoo! Finance Canada • 6h ago
Minerva Neurosciences, Inc. (NERV) Seasonal Returns ChartYahoo! Finance Canada report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
Why NERV Stock surged +3.57% Today — RQD Quant Desk Flash
$2.32 +3.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.33
Minerva Neurosciences Inc (NERV) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $107.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NERV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NERV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Minerva Neurosciences Inc (NASDAQ: NERV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.32 (+3.57% 1D, market cap $107.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NERV ranks #586 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NERV compare to IMUX and UNCY in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NERV carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMUX (Immunic Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $106.4M) and UNCY (Unicycive Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $106.1M). Among the 5-stock peer group, NERV leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NERV?
▼
Per NERV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001598646), Minerva Neurosciences Inc generated $0 in revenue, -$293.4M in net income, and -$13.5M in free cash flow against $98.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.33 (+0.45%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NERV)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY NERV SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.89-19.7% Next Q
46
Q2 (-2Q)Grade D$2.32-5.2% Next Q
43
Q3 (-1Q)Grade D$2.20+5.5% Next Q
41
CurrentGrade D-$2.32-7.8% Hist 90D α
38
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NERV Turnaround Squeeze
While NERV currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.44) and Max Pain ($2.44) forces dealer call-delta covering toward $9.24.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NERV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NERV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NERV Stock surged +3.57% Today — RQD Quant Desk Flash
Minerva Neurosciences Inc (NERV) surged +3.57% to $2.32, trading at 5% of its 52-week range ($1.96 – $8.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($1.96 – $8.8) with RSI-14 at 37.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.32 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NERV Headlines & Catalysts
MARKET WIREBarron's • 9h ago
Minerva Neurosciences Inc. Research & Ratings | NERVBarron's report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 12h ago
No FDA-approved treatments exist for schizophrenia's negative symptoms. Experts will discuss a drug still in testing.Stock Titan report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 15h ago
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in LondonYahoo Finance report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 18h ago
A live webcast will carry Minerva's Nov. 16 talk from London.Stock Titan report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 21h ago
Minerva Neurosciences (NERV) Holds Near $2.40 as Traders Eye Resistance - Institutional Volumehttps://www.siam.in/ report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Minerva (NERV) Advances +9.05% as Buying Pressure Builds 2026-10-21 - Sector Sentimenthttps://www.siam.in/ report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 5d ago
Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of SchizophreniaBURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorder
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NERV)
- ✓Walkthrough of NERV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NERV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.35%▼ SUPPORT BREAKDOWN
2026-11-02O $2.34H $2.43L $2.32C $2.32VOL 6.7K
RES: $5.38SUP: $3.21SMA50: $3.44SMA200: $4.89
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NERV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NERV today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NERV. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NERV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NERV)
Health Care Rank #586 of 1016
⚔️ IMUX vs NERV Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NERV vs. IMUX, UNCY, OKUR, ORGO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Minerva Neurosciences Inc (NERV) ranks #586 by composite RQD confidence (38/100, grade D-) and #650 by equity capitalization ($107.0M). Within this direct 5-issuer industry benchmark cohort, NERV leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. ORGO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with NERV at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NERV
ACTIVE
Minerva Neurosciences Inc | D- | 38/100 | — | — | -35.0% | +3.57% | $107.0M | Benchmark Subject |
| IMUX Immunic Inc. | D- | 38/100 | — | — | -35.0% | -3.66% | $106.4M | /imux-vs-nerv → |
| UNCY Unicycive Therapeutics Inc. | D | 45/100 | — | — | -35.0% | -1.84% | $106.1M | /uncy-vs-nerv → |
| OKUR OnKure Therapeutics Inc. (Class A) | D | 46/100 | — | — | -35.0% | 0.00% | $106.1M | /okur-vs-nerv → |
| ORGO Organogenesis Holdings Inc. (Class A) | D | 50/100 | — | — | 17.1% | -6.20% | $105.4M | /orgo-vs-nerv → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001598646In its most recent audited fiscal period (FY2025, filed 2025-12-31), Minerva Neurosciences Inc (NERV) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$293.4M, operating cash flow of -$13.5M, and free cash flow of -$13.5M (+30.9% YoY). On the balance sheet, NERV closed FY2025 with $98.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$293.4M | -$13.5M | -$13.5M | $98.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $1.4M | -$19.6M | -$19.6M | $37.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$30.0M | -$14.8M | -$14.8M | — | — |
3. NERV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NERV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Minerva Neurosciences Inc (NASDAQ: NERV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.32 (+3.57% 1D, market cap $107.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NERV ranks #586 in composite RQD confidence.
How does NERV compare to IMUX and UNCY in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NERV carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMUX (Immunic Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $106.4M) and UNCY (Unicycive Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $106.1M). Among the 5-stock peer group, NERV leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NERV?
Per NERV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001598646), Minerva Neurosciences Inc generated $0 in revenue, -$293.4M in net income, and -$13.5M in free cash flow against $98.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NERV trading relative to its 50-day, 200-day, and 52-week technical levels?
NERV last traded at $2.32 (+3.57% on volume of 394,698 shares), positioning the stock -32.56% below its 50-day simple moving average ($3.44) and -52.56% below its 200-day simple moving average ($4.89). Across its 52-week range of $1.96 to $8.80, NERV sits at the 5.3% percentile with a 14-day RSI of 37.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.03 to $2.61).
NERV Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NERV stock moving today?
Why NERV Stock surged +3.57% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 38/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
NERV — Minerva Neurosciences Inc: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:43:51Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, NERV scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine: 9 / 20. Per the RQD rating, ROIC is -35% and FCF yield is -12.63%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow, so any valuation rests on expectations of future change rather than current cash output.
- Whale 13F Flow: 8 / 20. The RQD rating cites institutional accumulation and options positioning as the basis for this pillar. Flow signals of this kind can indicate changing sponsorship, but the source data does not provide the underlying 13F holdings, so the pillar cannot be verified against specific filings here.
- Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, which indicates limited insider-side conviction signals in the data.
- Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market, offering no defensive cushion.
- Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These metrics point to a balance sheet that is neither clearly distressed nor clearly strong, with weak internal scoring on the Piotroski measure.
Taken together, the investor implication is that upside depends on a shift in the company's cash-generation profile, which the current data does not show. The valuation tradeoff is that a $107.0M market capitalization with negative returns and cash flow leaves little current earnings support for the price.
Business
Minerva Neurosciences Inc (NERV) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.1B. The source data does not describe its products, customers, or revenue model. Per the FY 2025 financials, reported revenue is $0.0M.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-15.1M | $-293.4M | N/A | $-13.5M | $82.3M | N/A |
| FY 2024 | $0.0M | $-21.8M | $1.4M | N/A | $-19.6M | $21.4M | N/A |
| FY 2023 | $0.0M | $-23.1M | $-30.0M | N/A | $-14.8M | N/A | N/A |
Per the SEC financials, reported revenue is $0.0M in each period and operating income is negative across all three years. Gross, operating, and net margins are each listed as 0% in the market data. Per the market data, ROIC is -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Per the SEC financials, cash rose to $82.3M at FY 2025 from $21.4M at FY 2024, while FY 2025 net income was $-293.4M against a FY 2024 figure of $1.4M.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the headlines reference the following items, all flagged YELLOW with MARKET WIRE impact:
- Coverage of a Jefferies Global Healthcare Conference presentation in London, with a related note that the talk is scheduled for Nov. 16 and will be carried by a live webcast.
- A Stock Titan item on schizophrenia negative symptoms, noting that no FDA-approved treatments exist for that indication and that experts will discuss a drug still in testing.
- A market commentary item referencing the stock holding near $2.40 with traders watching resistance.
- Seasonal returns and research/ratings pages from Yahoo! Finance Canada, Barron's, and Yahoo Finance, which the source describes only generically.
Risk watch items: the source data does not establish the outcome of any clinical testing, and the news feed does not report trial results. The Butterfly supply-chain graph reports no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks beyond the sector and industry classification already noted.
Open Questions
- What are the specific outcomes and timelines of the clinical program referenced in the news feed, and what is the status of the drug described as still in testing?
- What drove the FY 2025 net loss of $-293.4M against operating income of $-15.1M, and what non-operating items account for the gap?
- What are the company's reported debt obligations, given that debt is N/A in every period?
- Which institutions hold the shares, and do the 13F flows referenced in the RQD rating reflect accumulation or reduction?
- What is the company's cash runway given FCF of $-13.5M in FY 2025 against cash of $82.3M?
NERV Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Minerva Neurosciences Inc (NERV) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 6h ago
Minerva Neurosciences, Inc. (NERV) Seasonal Returns Chart Yahoo! Finance Canada report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Barron's • 9h ago
Minerva Neurosciences Inc. Research & Ratings | NERV Barron's report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 12h ago
No FDA-approved treatments exist for schizophrenia's negative symptoms. Experts will discuss a drug still in testing. Stock Titan report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 15h ago
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London Yahoo Finance report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 18h ago
A live webcast will carry Minerva's Nov. 16 talk from London. Stock Titan report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 21h ago
Minerva Neurosciences (NERV) Holds Near $2.40 as Traders Eye Resistance - Institutional Volume https://www.siam.in/ report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Most Active Stocks Today: U.S. Market TradingKey report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Minerva (NERV) Advances +9.05% as Buying Pressure Builds 2026-10-21 - Sector Sentiment https://www.siam.in/ report covering Minerva Neurosciences Inc (NERV) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NERV Bull vs. Bear Conversation Board — What's Your Call at $2.32?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NERV 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.97 (-12.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is NERV (D- • RQD 38/100) a Buy at $2.24?
Welcome to the NERV (Minerva Neurosciences Inc) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.75 (-21.9%)
Spot @ $2.24 Pump the brakes on NERV — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on NERV, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Minerva Neurosciences Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $2.69 (+20.1%)
Spot @ $2.24 NERV cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on NERV, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.24 (52-wk range $1.99 - $2.49), any beat on forward guidance forces shorts and underweight funds to chase.